Overview

Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer

Status:
Active, not recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to compare the effectiveness and safety of FKB238 against Avastin® in men and women with advanced/recurrent non squamous non-small cell lung cancer

Phase:

Phase 3

Details

Lead Sponsor:

Centus Biotherapeutics Limited

Treatments:

Albumin-Bound Paclitaxel
Bevacizumab
Carboplatin
Paclitaxel